Daniel R. Omstead
President and Chief Executive Officer @ Tekla Capital Management
Boston, United States
Daniel R. Omstead is a Series C investor at Tekla Capital Management in Boston focused on Health Care and Biotechnology. Daniel R. Omstead, Ph.D., is President and Chief Executive Officer of Tekla Capital Management, LLC. He is also President of H&Q Lifesciences Investors and H&Q Healthcare Investors, two NYSE listed closed-end mutual funds that make venture and public equity investments principally in small, emerging healthcare-related companies. Priorto joining Tekla, Dan was President and CEO of Reprogenesis, Inc. a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dan was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson and Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, Dan participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dan holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Daniel R. Omstead invests in
Stages Daniel R. Omstead invests in
Countries Daniel R. Omstead invests in
Investment Focus
Industry
- Health Care 3 (60%)
- Biotechnology 2 (40%)
- Medical 1 (20%)
- Therapeutics 1 (20%)
- Manufacturing 1 (20%)
Stage
- Series C 3 (60%)
- Series D 1 (20%)
Country
- United States 2 (40%)
- Canada 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Milestone Pharmaceuticals
|
Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrialarrhythmias and angina. | $80M / Series D / Oct 25, 2018 | |
|
Milestone Pharmaceuticals
|
Milestone Pharmaceuticals is a drug development company developing novel small molecule therapeutics based on clinically validated mechanisms for cardiovascular diseases. Milestone's lead product is a novel and potent short-acting calcium channel antagonist for the systemic treatment of transient cardiovascular conditions such as atrialarrhythmias and angina. | $55M / Series C / Aug 01, 2017 | |
IlluminOss Medical
|
IlluminOss Medical, Inc. is a commercial-stage medical device company offering a unique, minimally invasive technology for fracture repair and stabilization. The Company utilizes a light-curable polymer contained within an expandable balloon to create a patient-conforming intramedullary implant for bone stabilization. The revolutionary, minimallyinvasive technology is particularly applicable for repair and treatment of patients with osteoporotic and compromised bone. The IlluminOss system is CE-marked and FDA-cleared for a variety of anatomical sites, with further indications pending. | $28M / Series C / Sep 27, 2012 | |
Eleme Medical
|
Elemé Medical, Inc. is a venture backed aesthetics company dedicated to providing market-leading technology in all areas of body shaping. The newly launched SmoothShapes® XV will revolutionize how cellulite is treated and introduce exciting new protocols for pre and post liposuction care. With 50% more laser power, SmoothSpeed™ audible &visual treatment guidance and a portable, sleek console design, SmoothShapes XV is an ideal way to add non-invasive body shaping to a practice. SmoothShapes XV is the newest product launched by the Company and joins the original SmoothShapes launched in 2008, both products are a CE Marked, FDA-cleared medical devices for the temporary reduction in the appearance of cellulite.Both SmoothShapes systems are based on the company's proprietary Photomology® platform – a process that treats cellulite and subcutaneous fat by combining dynamic light and laser energy along with mechanical manipulation (vacuum and massage). The system addresses the physical manifestations of cellulite and its underlying causes providing long lasting results that patients can see and feel.Targets include plastic surgeons, aesthetic dermatologists, medical spas and other aesthetic physicians. According to Global Body Shaping Market Analysis, body shaping is one of the top growth areas in the Aesthetics market with 19% growth through the year 2012. The global aesthetics market is projected to grow from $5.0 billion in 2008 to $8.1 billion by 2011. | $18M / Series C / Jul 16, 2008 | |
Idun Pharmaceuticals
|
IDUN Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of human therapeutics to control apoptosis. Its products under Phase 2 and preclinical trials include drugs for liver disease, CNS diseases, inflammation, and cancer, as well as IDN-6556 for the treatment of liver diseases in patients infected withHepatitis C virus. The company was founded in 1993 and is based in San Diego, California. As of July 30, 2010, IDUN Pharmaceuticals, Inc. operates as a subsidiary of Conatus Pharmaceuticals Inc. | Series A / Dec 09, 2002 |
Co-Investors
About Tekla Capital Management
Tekla Capital Management LLC is a registered investment adviser based in Boston, Massachusetts, and is currently the investment adviser for two closed-end equity funds, H&Q Healthcare Investors and H&Q Life Sciences Investors. The Funds invest in growth equities, both public and private, in the healthcare and life sciences industries.
Tekla Capital Management Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alan Kwan
Senior Analyst
|
|||
|
Daniel R. Omstead
President and Chief Executive Officer
|
|||
|
Jason C. Akus
Senior Vice President, Research
|
|||
|
Jenny Fowler
Fund Administration Senior Associate
|
|||
|
Kolotioloma Silue
Manager of Fund Administration
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Daniel R. Omstead invest in?
Daniel R. Omstead invests primarily in Health Care, Biotechnology and Medical startups, most often at Series C and Series D stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Daniel R. Omstead last invest?
The most recent investment recorded for Daniel R. Omstead closed in Oct 2018. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
